<SEC-DOCUMENT>0001193125-19-170206.txt : 20190611
<SEC-HEADER>0001193125-19-170206.hdr.sgml : 20190611
<ACCEPTANCE-DATETIME>20190611161653
ACCESSION NUMBER:		0001193125-19-170206
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190606
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190611
DATE AS OF CHANGE:		20190611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Premier, Inc.
		CENTRAL INDEX KEY:			0001577916
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36092
		FILM NUMBER:		19891175

	BUSINESS ADDRESS:	
		STREET 1:		13034 BALLANTYNE CORPORATE PLACE
		CITY:			CHARLOTTE
		STATE:			NC
		ZIP:			28277
		BUSINESS PHONE:		704-357-0022

	MAIL ADDRESS:	
		STREET 1:		13034 BALLANTYNE CORPORATE PLACE
		CITY:			CHARLOTTE
		STATE:			NC
		ZIP:			28277
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d659470d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;8-K</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported):&nbsp;June 6, 2019 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Premier, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36092</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">35-2477140</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>13034 Ballantyne Corporate Place </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Charlotte, NC 28277 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(704)&nbsp;357-0022</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Class&nbsp;A Common Stock, $0.01 Par Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>PINC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>NASDAQ Global Select Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405) or <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2).</FONT> Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entry into a Material Definitive Agreement. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2019, Premier, Inc. (the &#147;Company&#148;) announced that its consolidated subsidiaries, Commcare Pharmacy &#150; FTL, LLC, a Florida limited
liability company (&#147;Commcare&#148;), Acro Pharmaceutical Services LLC, a Pennsylvania limited liability company (&#147;Acro&#148; and, together with Commcare, the &#147;Sellers&#148;), NS3 Health, LLC, a Florida limited liability company (the
&#147;Equity Holder&#148;), and the Company, for limited purposes, entered into an Asset Purchase and Sale Agreement (the &#147;Asset Purchase Agreement&#148;), dated as of May&nbsp;6, 2019, with ProCare Pharmacy, L.L.C., a Rhode Island limited
liability company (the &#147;Buyer&#148;), an affiliate of CVS Health Corporation, pursuant to which Buyer agreed to purchase from the Sellers prescription files and records and certain other assets (collectively, the &#147;Assets&#148;) used in the
Company&#146;s specialty pharmacy business (the &#147;Specialty Pharmacy Business&#148;), for a cash purchase price of $22.5&nbsp;million, plus an amount equal to the value of pharmaceutical inventory up to $20&nbsp;million, subject to certain
adjustments (the &#147;Transaction&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2019, the Sellers, the Equity Holder, the Company and the Buyer executed the First Amendment
to Asset Purchase and Sale Agreement (the &#147;Amendment&#148;). The Amendment revised a <FONT STYLE="white-space:nowrap">pre-closing</FONT> purchase price adjustment mechanism that is reflected in the proceeds set forth below, and made other
technical amendments to facilitate the transfer of the Assets and to clarify the original intentions of the parties. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Completion of Acquisition or Disposition of Assets. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under Item 1.01 above is incorporated by reference into this Item 2.01. The Transaction discussed above closed on June&nbsp;7<B>,</B>
2019. The Company received aggregate proceeds at closing of approximately $22.25&nbsp;million, and expects to receive approximately $7.6&nbsp;million on or about June&nbsp;12, 2019 related to the Buyer&#146;s acquisition of a portion of the
Sellers&#146; pharmaceutical inventory. The Company may receive additional proceeds, to the extent not offset by post-closing obligations of the Sellers, of up to approximately $12.4 million from the Buyer in connection with the acquisition of the
Sellers&#146; remaining pharmaceutical inventory. The proceeds to be received in the Transaction will be used primarily to fund costs associated with the Company&#146;s wind down and exit from the Specialty Pharmacy Business, and for general
corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Premier and its affiliates, nor any director or officer of Premier, has any material relationship, other than with respect to
the Transaction, with the Buyer or CVS Health Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information provided under Item 1.01 and Item 2.01 is a summary of certain portions of the
Asset Purchase Agreement and the Amendment and does not purport to be a complete description and is subject to, and qualified in its entirety by, (i)&nbsp;the information provided under Item 1.01 of Premier&#146;s Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed on May&nbsp;6, 2019 and (ii)&nbsp;the full text of the Asset Purchase Agreement and the Amendment, which are included as Exhibit&nbsp;2.1 and Exhibit&nbsp;2.1.1, respectively, to this Current
Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> To the extent not superseded by this <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> Item 1.01 of Premier&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed on May&nbsp;6, 2019 (and no other Item of such <FONT STYLE="white-space:nowrap">Form&nbsp;8-K)</FONT> is incorporated herein by reference herein. Each of Exhibit&nbsp;2.1 and Exhibit&nbsp;2.1.1 is
intended to provide investors and security holders with information regarding the terms of the Asset Purchase Agreement and the Amendment, respectively, but is not intended to provide any other financial information about the Company or its
subsidiaries or affiliates. The representations, warranties, and covenants contained in the Asset Purchase Agreement and the Amendment were made only for purposes of such agreements and as of specific dates, are solely for the benefit of the parties
to such agreements, may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk among the parties thereto instead of establishing these matters
as facts, and may be subject to standards of materiality applicable to the parties that differ from those applicable to investors. Investors should not rely on the representations, warranties, or covenants or any description thereof as
characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties, and covenants may change after the date of
such agreements, which subsequent information may or may not be fully reflected in the Company&#146;s public disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Items 2.05, 2.06 and 7.01 of
Premier&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on May&nbsp;6, 2019 are not incorporated herein by reference and not a part of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements made herein that are not statements of historical or current facts, including, but not limited to, the ultimate amount of proceeds received in the
Transaction and use of such proceeds, are &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995.&nbsp;Forward-looking statements may involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements of the Company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly,
readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include
terms such as &#147;believes,&#148; &#147;belief,&#148; &#147;expects,&#148; &#147;estimates,&#148; &#147;intends,&#148; &#147;anticipates&#148; or &#147;plans&#148; to be uncertain and forward-looking. Forward-looking statements may include
comments as to the Company&#146;s beliefs and expectations as to future financial performance, events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the Company&#146;s control.&nbsp;More
information on potential factors that could affect the Company&#146;s financial results is included from time to time in the &#147;Cautionary Note Regarding Forward-Looking Statements,&#148; &#147;Risk Factors&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of the Company&#146;s periodic and current filings with the SEC and made available on the Company&#146;s website at <U>investors.premierinc.com</U>.&nbsp;Forward
looking statements speak only as of the date they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events that occur after that date, or
otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibits. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1577916/000119312519138450/d736443dex21.htm">Asset Purchase and Sale Agreement, dated May&nbsp;
6, 2019, by and among Commcare Pharmacy &#150; FTL, LLC, Acro Pharmaceutical Services, LLC, NS3&nbsp;
Health, LLC, Premier, Inc., and ProCare Pharmacy, L.L.C. (filed as Exhibit 2.1 to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on May&nbsp;6, 2019 and incorporated herein by reference)</A>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d659470dex211.htm">First Amendment to Asset Purchase and Sale Agreement, dated June&nbsp;
6, 2019, by and among Commcare Pharmacy &#150; FTL, LLC, Acro Pharmaceutical Services, LLC, NS3 Health, LLC, Premier, Inc., and ProCare Pharmacy, L.L.C.</A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Premier, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Susan D. DeVore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Susan D. DeVore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: June&nbsp;11, 2019 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1.1
<SEQUENCE>2
<FILENAME>d659470dex211.htm
<DESCRIPTION>EX-2.1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FIRST AMENDMENT TO ASSET PURCHASE AND SALE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This FIRST AMENDMENT TO ASSET PURCHASE AND SALE AGREEMENT (this &#147;<U>First Amendment</U>&#148;) is made and entered into as of
June&nbsp;6, 2019, by and among Commcare Pharmacy &#150; FTL, LLC, a Florida limited liability company (&#147;<B>Commcare</B>&#148;), Acro Pharmaceutical Services, LLC, a Pennsylvania limited liability company (&#147;<B>Acro</B>&#148; and together
with Commcare, &#147;<B>Seller</B>&#148;), NS3 Health, LLC, a Florida limited liability company<B> </B>(&#147;<B>Equity Holder</B>&#148;), Premier, Inc., a Delaware corporation (&#147;<B>Premier</B>&#148;), and ProCare Pharmacy, L.L.C., a Rhode
Island limited liability company (&#147;<B>Buyer</B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>R E C I T A L S </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto are parties to that certain Asset Purchase and Sale Agreement, dated as of May&nbsp;6, 2019 (the
&#147;<U>Purchase Agreement</U>&#148;), pursuant to which Seller has agreed to sell, and Buyer has agreed to buy certain assets relating to the specialty pharmacy businesses located at (i)&nbsp;855&nbsp;SW 78th Avenue, Plantation, FL (the
&#147;<U>Plantation Pharmacy</U>&#148;), (ii) 313 Henderson Drive, Sharon Hill, PA (the &#147;<U>Sharon Hill Pharmacy</U>&#148;), and (iii)&nbsp;7891&nbsp;Stage Hills Boulevard, Suite 111, Memphis, TN (the &#147;<U>Memphis Pharmacy</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;<U>Section 19(l)</U> of the Purchase Agreement provides, in part, that the Purchase Agreement may be amended by an
agreement in writing signed by all parties thereto.&nbsp;In accordance with <U>Section</U><U></U><U>&nbsp;19(l)</U> of the Purchase Agreement, the parties desire to amend certain terms of the Purchase Agreement pursuant to the terms set forth
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, the parties hereto hereby agree as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Amendments</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The phrase &#147;and solely for purposes of <U>Section</U><U></U><U>&nbsp;9</U>, and
<U>Section</U><U></U><U>&nbsp;13</U>&#148; in the introduction to the Purchase Agreement shall be replaced with the following &#147;and solely for purposes of <U>Section</U><U></U><U>&nbsp;9</U>, <U>Section</U><U></U><U>&nbsp;13</U>, and <U>Schedule
4(h)</U>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;1(a)(ii)</U> of the Purchase Agreement is amended and restated
in its entirety as follows (with additions reflected in bold and underlined and deletions reflected in bold and stricken): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(ii)
<I>Prescription Files</I>. All prescription files, records related to drug acquisition and disposition, inventory records held by and inventory and dispensing data utilized, maintained and/or generated with respect to such prescription files and
records<B> </B>by Seller in the course of operating the Business (hereinafter, collectively, &#147;<B>Seller&#146;s Rx Data</B>&#148;) <B><STRIKE><strike><u>from the Date of Inventory (as hereinafter defined) and going back no less than the greater
of (i)</u></strike></STRIKE></B><B><STRIKE></STRIKE></B><B><U></U><STRIKE></STRIKE></B><B><STRIKE><strike><u>&nbsp;the period of time required by federal and state Law (as hereinafter defined) and
(ii)</u></strike></STRIKE></B><B><STRIKE></STRIKE><U></U><STRIKE></STRIKE></B><B><STRIKE><strike><u>&nbsp;two (2) years (the &#147;Required Time Period&#148;)</u></strike></STRIKE></B><B><U> as set forth on Schedule 1(a)(ii)</U></B><U>.</U>
Seller&#146;s Rx Data shall include all hard copy prescriptions, signature logs, patient profiles, patient refill histories, patient lists, and patient data and information derived from patient loyalty, credit, and similar programs <B><U>(&#147;Hard
Copy Rx Data&#148;)</U></B>, and all electronic data of the same maintained in any format by Seller. <B><STRIKE><strike><u>If Seller has not operated the Business for the Required Time Period prior to the Date of Inventory, the Required Time Period
shall </u></strike></STRIKE></B> </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>
<strike><u>be such shorter period as Seller has operated the Business.</u></strike> <U>All Hard Copy Rx Data and Seller&#146;s Rx Data held in the CareTend Pharmacy System shall be transferred to
Buyer at or before Closing. The Parties acknowledge and agree that the transfer of the Seller&#146;s Rx Data located in the CPR+ system, RxVector system, and Rx30 system may not be completed on the date of Closing. Seller shall use commercially
reasonable efforts to transfer all of Seller&#146;s Rx Data to Buyer as of the date of Closing, and in no event shall the transfer occur more than forty-five (45)</U><U></U><U>&nbsp;days following the date of Closing.&#148;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The first sentence of <U>Section</U><U></U><U>&nbsp;1(c)</U> of the Purchase Agreement is amended by inserting the
following as a new subsection (xi)&nbsp;at the end thereof: &#147;and (xi)&nbsp;the controlled substances located at, or in transit to, the Pharmacies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The second sentence of <U>Section</U><U></U><U>&nbsp;1(d)</U> of the Purchase Agreement is amended and restated in
its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Subject to the Holdback Amount (as hereinafter defined) and any other adjustments set forth in this
Agreement, including without limitation the&nbsp;adjustments set forth in <U>Section</U><U></U><U>&nbsp;4(b)</U> and <U>Schedule 4(h)</U>, the aggregate amount to be paid by Buyer to Seller with respect to the Assets shall equal
(i)&nbsp;<B><U>Twenty Two Million Two Hundred and Fifty Thousand and 00/100 Dollars ($22,250,000)</U></B> <B><strike><u><FONT STYLE="white-space:nowrap">Twenty-Two</FONT> Million Five Hundred Thousand and 00/100 Dollars
($22,500,000.00)</u></strike></B> (the &#147;<B>Closing Payment</B>&#148;), plus (ii)&nbsp;the amount of the Inventory Payment (collectively, the &#147;<B>Purchase Price</B>&#148;).&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The seventh sentence of <U>Section</U><U></U><U>&nbsp;2(d)</U> of the Purchase Agreement is amended and restated in
its entirety as follows (with additions reflected in bold and underlined and deletions reflected in bold and stricken): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;In
addition, Seller shall arrange to have the websites <B><U>used in connection with the Pharmacies that are included in the Transferred Intellectual Property (the &#147;Transferred Websites&#148;)</U></B><B> </B>and social media accounts used in
connection with the Pharmacies that are included in Transferred Intellectual Property <B><U>(the </U></B><U>&#147;</U><B><U>Transferred Social Media Accounts,&#148; collectively with the Transferred Websites referred to as</U></B><B>
</B>&#147;Transferred Websites and Social Media Accounts&#148;) prepared, effective as of the Closing, to post a message notifying the public of the transfer of&nbsp;the prescription files to Buyer from Seller as described herein and providing
contact information for Buyer and its pharmacies and/or a link to Buyer&#146;s websites as set forth in a written notice by Buyer to Seller.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;2(f)</U> of the Purchase Agreement is amended and restated in its entirety as follows
(with additions reflected in bold and underlined and deletions reflected in bold and stricken): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DSCSA</U>. Seller and Equity
Holder agree to provide or to cause to be provided to Buyer <B><U>on or prior to Closing, or as soon as practicable after Closing, (a)</U></B><B><U></U></B><B>&nbsp;<strike><u>all</u></strike></B> product tracing information that is required in
connection with requirements under the Drug Supply Chain Security Act (&#147;<B>DSCSA</B>&#148;) for the prescription merchandise to be purchased by Buyer under <U>Section</U><U></U><U>&nbsp;1(a)(i)</U> hereof <B><U>that was obtained by Seller from
McKesson </U></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<B><U>Corporation, its Affiliates or its systems (collectively, &#147;McKesson&#148;)</U></B>, including, without limitation, transaction histories, transaction statements, and transaction
information, for such merchandise (collectively, the &#147;<B><U>McKesson </U></B><B>DSCSA Records</B>&#148;)<B><U>, and (b)</U></B><B><U></U></B><B><U>&nbsp;invoices from June 2016 through the Closing with respect to the prescription merchandise to
be purchased by Buyer under Section</U></B><B><U></U></B><B><U>&nbsp;1(a)(i) hereof that was acquired by Seller directly from the manufacturers of such prescription merchandise (such direct manufacturers, collectively, the &#147;Direct
Manufacturers,&#148; and such records, collectively, the &#147;Direct Manufacturer DSCSA Records&#148;).</U></B><B><U></U></B><B><U>&nbsp;For a period of three years after the Closing, upon the prior written request of Buyer, Seller and Equity
Holder shall use commercially reasonable efforts to provide or to cause to be provided to Buyer product tracing information that are required by Buyer in connection with requirements under the DSCSA for the prescription merchandise purchased by
Buyer under Section</U></B><B><U></U></B><B><U>&nbsp;1(a)(i) hereof, including, without limitation, transaction histories, transaction statements, and transaction information, for any such merchandise determined to be acquired through sources other
than McKesson or Direct Manufacturers (collectively, the &#147;Additional DSCSA Records,&#148; and together with the McKesson DSCSA Records and the Direct Manufacturer DSCSA Records, the &#147;DSCSA
Records&#148;).</U></B><B><U></U></B><B><U></U></B><B> <STRIKE>At no additional cost to Buyer, Seller shall cooperate and assist Buyer, at least thirty (30)&nbsp;days prior to the Date of Inventory, in Buyer&#146;s efforts to effect a transfer of
the DSCSA Records.</STRIKE></B> Such cooperation shall include Seller taking such acts as may be necessary, including, without limitation, executing a release or authorization for the benefit of any third parties that are maintaining any DSCSA
Records on behalf of Seller, as may be necessary to facilitate the transfer of all DSCSA Records to Buyer.&nbsp;The terms and provisions of this Section&nbsp;2(f) shall survive the Closing.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;2(g)(4)</U> of the Purchase Agreement is hereby deleted in its entirety and replaced
as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;(4)&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally Omitted];&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;The last sentence of <U>Section</U><U></U><U>&nbsp;2(h)</U> of the Purchase Agreement is amended and restated in
its entirety as follows (with additions reflected in bold and underlined and deletions reflected in bold and stricken): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding the foregoing, Seller and its Affiliates shall have the right, from and after the Closing, to continue to use
Seller&#146;s Rx Data that has been <FONT STYLE="white-space:nowrap">de-identified</FONT> in compliance with the HIPAA Rules solely for <FONT STYLE="white-space:nowrap">non-specialty</FONT> pharmacy data analytics purposes <B><U>and/or</U></B> to
the extent necessary to fulfill Seller&#146;s obligations under agreements with third parties (including specialty pharmacy data analytics solely for purposes of fulfilling Seller&#146;s final obligations under manufacturer agreements).&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The last sentence of <U>Section</U><U></U><U>&nbsp;2(i)</U> of
the Purchase Agreement is amended and restated in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;In addition, the Parties acknowledge that the Buyer will
not take possession of any controlled substances that are included in the Inventory, and&nbsp;the Inventory Payment shall not include the value of the controlled substances. Seller shall maintain possession of all controlled substance inventory at
the Pharmacies. In consideration of Seller&#146;s disposal of the controlled substances inventory at the Pharmacies in compliance with DEA regulations and other applicable Laws, Buyer shall pay Seller a disposal fee equal to the value of the
controlled substances, not to exceed Sixteen Thousand Dollars ($16,000) (the &#147;<B>Controlled Substances Disposal Fee</B>&#148;). The Controlled Substances Disposal Fee shall be added to the Inventory Payment.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;2(j)</U> of the Purchase Agreement is amended and restated in its entirety as follows
(with additions reflected in bold and underlined and deletions reflected in bold and stricken): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acro </U><B><U>and Commcare
</U></B><U>Mark</U><B><U>s</U></B>. Seller shall, as it relates to the service mark &#147;ACRO PHARMACEUTICAL SERVICES&#148; (PTO Serial Number 88064446, filed with the PTO on August&nbsp;3, 2018) (the &#147;<B>Acro Mark</B>&#148;) <B><U>and the
service mark &#147;COMMCARE SPECIALTY PHARMACY&#148; (PTO Serial Number 88064495, filed with the PTO on August</U></B><B><U></U></B><B><U>&nbsp;3, 2018) (the &#147;Commcare Mark&#148;)</U></B>, (A) promptly notify Buyer if any opposition or request
for extension is filed with the PTO relating to the Acro Mark <B><U>and the Commcare Mark</U></B>, and (B)&nbsp;use commercially reasonable efforts to prosecute the Acro Mark <B><U>and the Commcare Mark</U></B> until the PTO issues a registration
certificate relating thereto (the &#147;<B><STRIKE>Acro</STRIKE></B><B> Registration Certificate</B><B><U>s</U></B>&#148;).&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;The following new <U>Section</U><U></U><U>&nbsp;2(k) </U>is added to the Purchase Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(k) <U>Termination of Transferred Social Media Accounts</U>. Prior to Closing, Seller shall take all reasonably necessary steps and
complete all reasonably necessary paperwork to have all Transferred Social Media Accounts terminated by LinkedIn and Facebook as soon as practicable after the Closing. In the event that the Transferred Social Media Accounts are not terminated by
Closing, Seller further convents to provide Buyer with reasonable assistance post-Closing as reasonably necessary to terminate the Transferred Social Media Accounts post-Closing.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;The following new <U>Section</U><U></U><U>&nbsp;2(l) </U>is added to the Purchase Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(l) <U>Automatic Replies and Information</U>. During the sixty (60)&nbsp;day period following the Closing, Seller shall cause an
automatic reply to be sent from the <FONT STYLE="white-space:nowrap">e-mail</FONT> of each former Seller employee that becomes a Buyer employee in connection with the transactions contemplated hereby (&#147;<B>Transitioned Employees</B>&#148;),
which automatic reply shall indicate that such Transitioned Employee is now an employee of Buyer and shall include Buyer e-mail and telephone contact information for such Transitioned Employee as mutually agreed by the parties. Promptly after a
Seller sales representative becomes a Transitioned Employee, Seller shall provide to Buyer a roster (including assigned customer and contact information) and a &#147;visit&#148; log (excluding any notes) with respect to such former Seller sales
representative.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;The following new <U>Section</U><U></U><U>&nbsp;2(m) </U>is added
to the Purchase Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(m) <U>Business Associate Agreement</U>. Following the Closing, in the event (i)&nbsp;Buyer is required
pursuant to <U>Section</U><U></U><U>&nbsp;10(b)</U> of this Agreement to provide to Seller any Seller&#146;s Rx Data that constitutes Protected Health Information (&#147;<U>Protected Data</U>&#148;), or (ii)&nbsp;Seller otherwise requests access to
Protected Data and Buyer agrees to provide such Protected Data to Seller, and under each of the foregoing (i)&nbsp;and (ii) Buyer and Seller mutually agree that a Business Associate Agreement is required under the HIPAA Rules, Buyer and Seller agree
to negotiate in good faith a Business Associate Agreement covering the use and disclosure of such Protected Data.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;4(e)</U> of the Purchase Agreement is amended and restated in its entirety as follows
(with additions reflected in bold and underlined and deletions reflected in bold and stricken): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>&#147;Closing</U>. The closing of the
purchase and sale of the Assets from the Seller to Buyer and the assumption by Buyer of the Assumed Liabilities (if&nbsp;any) (hereinafter, a &#147;<B>Closing</B>&#148;) shall take place by facsimile or .pdf transmission of documents including
counterpart signature pages <B><U>by 9:00 am EST on the Date of Inventory and prior to completion of the physical inventory at the Pharmacies</U></B><U> </U><B><STRIKE><strike><u>upon completion of the physical inventory at the Pharmacies on the
Date of Inventory</u></strike></STRIKE></B>, subject to the satisfaction or waiver of the conditions precedent to Buyer&#146;s obligation and Sellers&#146; obligation to close set forth in this Agreement, including, without limitation, in
<U>Section</U><U></U><U>&nbsp;7</U> and <U>Section</U><U></U><U>&nbsp;8</U>. Possession and control of the applicable Assets<B> </B><B><U>with the exception of the Inventory</U></B>, and the risk of loss or damage to the applicable Assets<B>
</B><B><U>with the exception of the Inventory</U></B>, and responsibility for the Assumed Liabilities (if any), shall be transferred to Buyer upon Closing. <B><U>Possession and control of the Inventory and risk of loss or damage to the Inventory
shall be transferred upon the completion of the physical inventory, which will occur after the Closing, but not later than the end of the day of the Date of Inventory</U></B><B>. </B>Concurrently with the Closing, Buyer shall pay to Seller an amount
equal to the Closing Payment less the Holdback Amount, Seller&#146;s portion of the fee due to the Escrow Agent, and any amounts paid directly to Seller&#146;s secured creditors, by wire transfer to Seller&#146;s account in immediately available
funds. No later than three (3)&nbsp;Business Days following the Date of Inventory (the &#147;<B>Date of First Payment</B>&#148;), Buyer shall pay to Seller an amount equal to the Inventory Payment with respect to the First Inventory determined on
the Date of Inventory, by wire transfer to Seller&#146;s account in immediately available funds. No later than three (3)&nbsp;Business Days following the Date of <FONT STYLE="white-space:nowrap">True-Up</FONT> Inventory (the &#147;<B>Date of <FONT
STYLE="white-space:nowrap">True-Up</FONT> Payment</B>&#148;), Buyer shall pay to Seller an amount equal to the Inventory Payment with respect to the Second Inventory determined on the Date of <FONT STYLE="white-space:nowrap">True-Up</FONT>
Inventory. Buyer and Seller agree to execute and deliver (i)&nbsp;prior to the Date of First Payment (but to be dated as of the Date of First Payment), a closing statement with respect to the Inventory Payment for the First Inventory and
(ii)&nbsp;prior to the Date of <FONT STYLE="white-space:nowrap">True-Up</FONT> Payment (but to be dated as of the Date of <FONT STYLE="white-space:nowrap">True-Up</FONT> Payment, a closing statement with respect to the Second Inventory. By execution
of this Agreement, Seller agrees to the manner and form of payment described in this paragraph and that Buyer, upon making said payment in said manner and form, shall conclusively be deemed to have fulfilled its payment obligations hereunder.&#148;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;4(h)</U> of the Purchase Agreement
is amended and restated in its entirety as follows (with additions reflected in bold and underlined and deletions reflected in bold and stricken): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(h) <U>Additional Covenants</U>.&nbsp;Buyer, Seller<B><U>,</U></B> <STRIKE>and</STRIKE> Equity Holder<B><U>, and Premier</U></B> shall
comply with the provisions set forth in this Agreement<B><U> (as amended from time to time)</U></B>, including<B><U> Schedule 4(h) and</U></B> the <B><U>other </U></B>schedules hereto <B><U>(as amended from time to time)</U></B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;5(s)</U> of the Purchase Agreement is amended and restated in its entirety as follows
(with additions reflected in bold and underlined and deletions reflected in bold and stricken): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>.
<U>Schedule 5(s)</U> sets forth all registered patents, trademarks, domain names, and copyrights (and all applications related thereto) included in the Transferred Intellectual Property which is related to or used in the conduct of the Business.
Seller owns or possesses all right, title and interest in and to each item of Transferred Intellectual Property set forth on <U>Schedule 5(s)</U>. Upon consummation of the Closing, Buyer shall own or possess sufficient rights to use each item of
Transferred Intellectual Property, free and clear of any Liens, <B><U>with the exception of the Transferred Websites, which shall be transferred to the Buyer on the date that is ninety (90)</U></B><B><U></U></B><B><U>&nbsp;days following the
Closing</U></B>. The rights of Seller in such Transferred Intellectual Property are valid, effective and enforceable and, to the Knowledge of Seller, upon consummation of the Closing, the rights of Buyer in such Transferred Intellectual Property
will be valid, effective and enforceable. Any and all renewal and maintenance fees, annuities or other fees payable to any person to maintain the registered Transferred Intellectual Property as active and due prior to the Closing have been paid in
full. Seller has not received notice that the operation of the Business, as conducted by Seller, infringes the intellectual property rights of any person with respect to the Transferred Intellectual Property. No action by any person or entity
contesting the validity, enforceability, use, registration or ownership of any Transferred Intellectual Property is pending or, to the Knowledge of Seller, is threatened. Except as set forth on <U>Schedule 5(s</U>), to the Knowledge of Seller, no
person or entity is violating, misappropriating or infringing any Transferred Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;7(c)(xi)</U> of the Purchase Agreement is amended and restated in its entirety as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Seller shall have provided to Buyer the following with respect to the Transferred Intellectual Property <B><U>as of the
Date of Inventory</U></B>: (1)&nbsp;an intellectual property assignment agreement in the form attached hereto as <U>Exhibit D</U>, duly executed by Seller and Equity Holder,
<B><STRIKE><strike><u>(2)</u></strike></STRIKE></B><B><STRIKE></STRIKE></B><B><STRIKE><strike><u>&nbsp;all codes with respect to the domain name(s) transferred to Buyer pursuant to the foregoing assignment of domain
name(s)</u></strike></STRIKE></B><B><U>, </U></B><B><STRIKE></STRIKE></B><B><U><strike><u>(3)</u></strike></U><STRIKE></STRIKE></B><B><U> (2)</U></B> original certificates or certified copies of the originals issued by the PTO with respect to marks
that are Transferred Intellectual Property, <B><STRIKE>and</STRIKE></B> <B><strike><u>(4)</u></strike></B><B><U> (3)</U></B>&nbsp;the&nbsp;<B><STRIKE>Acro</STRIKE></B> Registration Certificate<B><U>s</U></B> <B><U>(to the extent available <FONT
STYLE="white-space:nowrap">pre-Closing,</FONT> otherwise, to be delivered when available post-Closing)</U></B>; and <B>(4)&nbsp;</B><B></B><B><U>reasonably necessary paperwork to have the Transferred Social Media Accounts terminated. All Transferred
Websites and codes with&nbsp;respect to the Transferred Websites shall be transferred to the Buyer within ninety (90)</U></B><B><U></U></B><B><U>&nbsp;days following the Closing</U></B>; and&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;The following is added to the Purchase Agreement as a new
<U>Section</U><U></U><U>&nbsp;7(c)(xiii)</U>: &#147;(xiii) Prior to the Date of Inventory, a Transition Services Agreement and, as applicable, a Business Associate Agreement for the access of PHI in relation to the services provided pursuant to such
Transition Services Agreement, each executed by Seller and Equity Holder in a form satisfactory to the Buyer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;The following is added to the Purchase Agreement as a new <U>Section</U><U></U><U>&nbsp;8(b)(viii)</U>:
&#147;(viii) Prior to the Date of Inventory, a Transition Services Agreement and, as applicable, a Business Associate Agreement for the access of PHI in relation to the services provided pursuant to such Transition Services Agreement, each executed
by Buyer in a form satisfactory to the Seller.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;7(d)</U> of the Purchase
Agreement is hereby deleted in its entirety and replaced as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;(d)&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally Omitted.]&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9(a)(ii) of the Purchase Agreement is hereby deleted in its entirety and replaced as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(ii)&nbsp;&nbsp;hire, engage, employ or interfere with the employment of, or attempt to hire, engage, employ or interfere with the
employment of, either directly or indirectly, the Identified Employees or any other employees of Buyer or any Affiliates of Buyer engaged in the Specialty Pharmacy Business in the Specialty Restricted Territory, or induce or attempt to induce,
either directly or indirectly, any of them to leave the employ of Buyer or any Affiliate, or violate the terms of his or her contract with Buyer or any Affiliate; provided, that (A)&nbsp;nothing in this <U>Section</U><U></U><U>&nbsp;9(a)(ii)
</U>shall prevent any person or entity from making a general solicitation which is not directed specifically to any of the employees of Buyer or any Affiliates of Buyer engaged in the&nbsp;Specialty Pharmacy Business in the Specialty Restricted
Territory), and (B)&nbsp;the continued employment of a Breaching Identified Individual by Seller or their Affiliates until July&nbsp;31, 2019 shall not be a violation of this <U>Section</U><U></U><U>&nbsp;9(a)(ii)</U> <B><U>and
(C)</U></B><B><U></U></B><B><U>&nbsp;the continued employment of an Identified Individual that has accepted</U></B><B> </B><B><U>Buyer&#146;s (or an Affiliate of Buyer&#146;s) Offer Package, but has not yet successfully completed Buyer&#146;s (or
such Affiliate&#146;s) standard hiring processes (including, without limitation, passing Buyer&#146;s (or such Affiliate&#146;s) background checks and drug screenings) by Seller or their Affiliates until July</U></B><B><U></U></B><B><U>&nbsp;31,
2019 shall not be a violation of this Section</U></B><B><U></U></B><B><U>&nbsp;9(a)(ii)</U></B>; or&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><U>Capitalized Terms</U></B><B>.</B> Except as defined herein, all capitalized terms shall have the
meanings assigned to such terms in the Purchase Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><U>Integration</U></B>. This First Amendment and the recitals, exhibits, schedules and certificates
referred to herein or delivered pursuant hereto shall constitute and shall be interpreted as a written modification to the Purchase Agreement and the recitals, exhibits, schedules and certificates referred to therein or delivered pursuant thereto
upon the execution by the each of the parties in accordance with <U>Section</U><U></U><U>&nbsp;19(l)</U> of the Purchase Agreement. In the event of a conflict between the terms of the Purchase Agreement or the recitals, exhibits, schedules or
certificates referred to therein or delivered pursuant thereto and this First Amendment or the recitals, exhibits, schedules or certificates referred to herein or delivered pursuant hereto with respect to the subject matter hereof, the terms of this
First Amendment and the recitals, exhibits, schedules and certificates referred to herein or delivered pursuant hereto shall control. Except as otherwise expressly set forth in this First Amendment and the recitals, exhibits, schedules and
certificates referred to herein or delivered pursuant hereto, all terms, conditions, representations, warranties, obligations and restrictions set forth in the Purchase Agreement and the recitals, exhibits, schedules and certificates referred to
therein or delivered pursuant thereto shall remain in full force and effect between the parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><U>Counterparts</U></B>. This First Amendment may be executed in two or more counterparts. Each
counterpart shall be deemed an original for purposes of establishing proof of this Amendment. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Remainder of this
page left intentionally blank. Signature page to follow.] </I></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THEREFORE</B>, the parties hereto have executed, or caused this First Amendment to Asset
Purchase Agreement to be executed by their duly authorized representatives, as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>SELLER:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Commcare Pharmacy &#150; FTL, LLC</B> a Florida limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Craig McKasson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Craig McKasson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Acro Pharmaceutical Services, LLC</B> a Pennsylvania limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Craig McKasson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Craig McKasson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>EQUITY HOLDER:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NS3 Health, LLC</B> a Florida limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Craig McKasson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Craig McKasson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>PREMIER:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Premier, Inc.,</B> a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Craig McKasson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Craig McKasson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>First Amendment to Asset Purchase and Sale Agreement </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>BUYER:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ProCare Pharmacy, L.L.C., a Rhode Island limited liability&nbsp;company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Syed A. Husain</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Syed A. Husain</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>First Amendment to Asset Purchase and Sale Agreement </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
